Amgen dismisses bone density concerns related to its weight-loss drug
Amgen said on Wednesday there was no link between its experimental weight-loss drug and changes in bone density, a day after those concerns wiped off more than $12 billion from the company's market value.
Amgen Defends Its Investigational Monthly Weight Loss Injection After Analyst Cites MariTide's Impact on Bone Density
Amgen addresses safety concerns for its weight loss drug MariTide after new data suggests a potential 4% reduction in bone density at the highest dose.
Amgen speaks out about bone density concerns with obesity drug
Amgen’s stock fell 7% after an analyst posted a note on MariTide’s influence on bone density which was noticed in a data spreadsheet.
Amgen defends obesity drug amid bone concerns
After a research note raised potential safety concerns with Amgen's lead obesity candidate, the company defended its drug and has asked the journal to issue a correction and add in the finalized data.
Amgen stock falls as analysts mull over weight loss drug's bone density data
Analysts cited data from a phase one study showing the highest dose of Amgen’s MariTide was linked to roughly 4% loss of bone mineral density over 12 weeks.
Amgen MariTide bone mineral density loss data ‘leaked,’ says Cantor Fitzgerald
Cantor Fitzgerald tells investors that MariTide’s Phase 1 data includes “a big surprise” as the supplemental appendix file
MarketWatch1d
Amgen Says No Link Between MariTide, Bone Density Loss
Amgen on Wednesday sought to allay concerns that its MariTide, investigational weight-loss shot could be linked to a loss of bone mineral density. Amgen shares fell more than 7% on Tuesday after ...
FierceBiotech1d
Hidden data on obesity prospect wipe $12B off Amgen market cap
The tab contains data on bone density changes in patients who received Amgen’s obesity prospect MariTide in a phase 1 ...
What’s Happening With Amgen Stock?
In this photo illustration, Amgen logo is displayed on a smartphone with a S&P ... [+] index website background. (Photo ...
Benzinga.com1d
Jim Cramer Says Eli Lilly's 'Pathetic' Stock Performance Could Get A Breather If Amgen Has Hidden Bone Risk Data After 7% Stock Drop
Amgen Inc.‘s AMGN stock dropped over 7% on Tuesday following revelations about bone density loss in early trials of its ...
Amgen dismisses bone density concerns related to its new weight-loss drug
Amgen said on Wednesday there was no link between its experimental weight-loss drug and changes in bone density, a day after ...
Amgen Says No Link Between MariTide And Changes In Bone Mineral Density
Wednesday said there is no association between administration of experimental weight loss drug MariTide and changes ...